SRGAP2B

SRGAP2B is a human-specific, partially truncated segmental duplication of the ancestral SRGAP2A gene that arose ~3.4 million years ago and encodes only a truncated F-BAR domain (PMID:22559943, PMID:22559944). It acts as an antagonist of its ancestral paralog: SRGAP2B protein is intrinsically unstable in neurons and, upon heterodimerization with SRGAP2A, drives proteasome-dependent reduction of SRGAP2A protein levels (PMID:31822692). Through this lowering of synaptic SRGAP2A, SRGAP2B together with SRGAP2C increases postsynaptic accumulation of SYNGAP1, and the resulting shift in the reciprocal SRGAP2A–SYNGAP1 antagonism sets a slowed (neotenic) tempo of human cortical synaptogenesis (PMID:39406239). SRGAP2B/C also act in human microglia to induce neotenic structural and functional maturation that non-cell-autonomously influences cortical synaptic development (PMID:38979266). SRGAP2B is functionally distinct from the closely related SRGAP2C: it lacks the arginine-targeting non-synonymous substitutions present in SRGAP2C and cannot by itself sustain long-lasting changes in synaptic density (PMID:31822692).

1. 2012 High

   Established the origin and structure of SRGAP2B, explaining how a human-specific paralog encoding only a partial F-BAR domain could exist as a candidate modifier of SRGAP2A function.

   Evidence Comparative genomic and sequence analysis using a haploid hydatidiform mole to resolve duplicated segments

   PMID:22559943 PMID:22559944

   Open questions at the time

   • Did not establish whether the truncated SRGAP2B protein itself is functional or merely a dominant-negative fragment
   • Did not directly test SRGAP2B-SRGAP2A interaction biochemically
2. 2012 High

   Showed that the SRGAP2B-derived paralog SRGAP2C dimerizes with and inhibits ancestral SRGAP2A, linking the duplication to neuronal phenotypes of migration and spine neoteny.

   Evidence Co-immunoprecipitation for dimerization plus in utero electroporation in mouse neocortex with morphological readouts

   PMID:22559943 PMID:22559944

   Open questions at the time

   • Focused on SRGAP2C; did not resolve the distinct contribution of SRGAP2B
   • Mechanism by which dimerization inhibits SRGAP2A activity not defined at this stage
3. 2019 Medium

   Defined the molecular mechanism of SRGAP2B antagonism and distinguished it from SRGAP2C, answering how a truncated paralog lowers ancestral protein activity.

   Evidence Co-IP heterodimerization, proteasome inhibitor treatment, live-cell protein stability imaging and synaptic density assays in cortical neurons

   PMID:31822692

   Open questions at the time

   • From a single lab; reciprocal in vivo validation of the proteasome-dependent destabilization limited
   • Did not identify the E3 ligase or degron mediating SRGAP2A turnover
   • Did not resolve why SRGAP2B alone cannot sustain synaptic density changes at the molecular level
4. 2024 High

   Placed SRGAP2B/C within a defined synaptic signaling axis, showing that lowering SRGAP2A raises postsynaptic SYNGAP1 and that this antagonism sets the tempo of human synaptogenesis.

   Evidence shRNA knockdown and combinatorial loss-of-function of SRGAP2B/C in human cortical neurons xenotransplanted into mouse cortex, with synaptic protein quantification and in vivo epistasis

   PMID:39406239

   Open questions at the time

   • SRGAP2B and SRGAP2C contributions assayed jointly, not separated
   • Direct biochemical link between SRGAP2A reduction and SYNGAP1 accumulation not fully resolved
5. 2024 Medium

   Extended SRGAP2B/C function beyond neurons, showing a cell-autonomous role in microglial neoteny that feeds back onto cortical synaptic development.

   Evidence Xenotransplantation of hiPSC-derived microglia into mouse brain plus mouse genetic loss- and gain-of-function with structural and functional readouts (preprint)

   PMID:38979266

   Open questions at the time

   • Preprint, not yet peer-reviewed
   • Distinct role of SRGAP2B versus SRGAP2C in microglia not separated
   • Molecular mediators of the non-cell-autonomous effect on synapses unknown

• How SRGAP2B's heterodimerization is converted into SRGAP2A proteasomal degradation, and what distinguishes its transient effects from the durable effects of SRGAP2C at the molecular level, remain unresolved.
• No E3 ligase or degron identified for SRGAP2A turnover
• No structural model of the SRGAP2B-SRGAP2A heterodimer
• SRGAP2B-specific (versus SRGAP2C) contributions to neuronal and microglial neoteny not isolated